muscarinic acetylcholine subtype 1 receptor antagonists (Vanderbilt University/Seaside Therapeutics)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namemuscarinic acetylcholine subtype 1 receptor antagonists (Vanderbilt University/Seaside Therapeutics)
Drug Alias Namemuscarinic M1 receptor antagonists (Vanderbilt University/Seaside Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor M1 antagonists
TargetsMuscarinic acetylcholine receptor M1
Therapy Area/IndicationsAutistic DisorderFragile X Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesVanderbilt University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeaside Therapeutics IncVanderbilt University
Active IndicationsN/A
Inactive IndicationsAutistic DisorderFragile X Syndrome

Other Information

ATC CodeN/A
Related LinksN/A